Charles River Laboratories International Inc. (CRL) recently have taken one step ahead with the beta value of 1.37

Witnessing the stock’s movement on the chart, on Thursday, Charles River Laboratories International Inc. (NYSE: CRL) had a quiet start as it plunged -2.09% to $182.73, before settling in for the price of $186.63 at the close. Taking a more long-term approach, CRL posted a 52-week range of $161.65-$275.00.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 12.89%. Meanwhile, its Annual Earning per share during the time was 14.84%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -6.23%. This publicly-traded company’s shares outstanding now amounts to $51.34 million, simultaneously with a float of $51.06 million. The organization now has a market capitalization sitting at $9.43 billion. At the time of writing, stock’s 50-day Moving Average stood at $196.34, while the 200-day Moving Average is $221.19.

Charles River Laboratories International Inc. (CRL) Ownership Facts and Figures

Nothing is more important than checking the behaviour of major investors towards the stock of the Diagnostics & Research industry. Charles River Laboratories International Inc.’s current insider ownership accounts for 1.10%, in contrast to 102.95% institutional ownership. According to the most recent insider trade that took place on Aug 08 ’24, this organization’s EVP, Corp Strategy & Develop sold 1,780 shares at the rate of 199.36, making the entire transaction reach 354,861 in total value, affecting insider ownership by 22,521.

Charles River Laboratories International Inc. (CRL) Earnings and Revenue Records

Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.51 per share during the current fiscal year.

Charles River Laboratories International Inc.’s EPS decrease for this current 12-month fiscal period is -6.23% and is forecasted to reach 10.45 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 3.24% through the next 5 years, which can be compared against the 14.84% growth it accomplished over the previous five years trading on the market.

Charles River Laboratories International Inc. (NYSE: CRL) Trading Performance Indicators

Let’s observe the current performance indicators for Charles River Laboratories International Inc. (CRL). It’s Quick Ratio in the last reported quarter now stands at 1.21. The Stock has managed to achieve an average true range (ATR) of 5.72. Alongside those numbers, its PE Ratio stands at $21.60, and its Beta score is 1.37. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.31. Similarly, its price to free cash flow for trailing twelve months is now 19.38.

In the same vein, CRL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 8.46, a figure that is expected to reach 2.42 in the next quarter, and analysts are predicting that it will be 10.45 at the market close of one year from today.

Technical Analysis of Charles River Laboratories International Inc. (CRL)

Going through the that latest performance of [Charles River Laboratories International Inc., CRL]. Its last 5-days volume of 0.83 million indicated improvement to the volume of 0.6 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 22.79% While, its Average True Range was 5.74.

Raw Stochastic average of Charles River Laboratories International Inc. (CRL) in the period of the previous 100 days is set at 3.40%, which indicates a major fall in contrast to 12.36% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 25.88% that was lower than 37.07% volatility it exhibited in the past 100-days period.